Human recombinant interferon-alpha-2 in the treatment of patients with hairy cell leukemia.
During the last 2 years, we have treated 14 hairy cell leukemia (HCL) patients with human recombinant interferon-2 alpha (Boehringer Ingelheim). The above group consisted of eight nonsplenectomized and six previously splenectomized progressive HCL patients. The patients received daily doses of 5 x 10(6) units of IFN for 3 months and two doses per week for the next 3 months thereafter by i.m. route. The therapy resulted in the complete (nine cases, = 64.3%) or partial (two cases = 14.3%) clinical and hematological remission (response rate 78.6%), with either disappearance or marked reduction in circulating and bone marrow hairy cells, decreased spleen size, and recovery of normal hemopoiesis. Apart from a transient flulike syndrome during the first 2 weeks of therapy, no other side effects were observed.
Skotnicki
A B
AB
Institute of Pediatrics, Cracow Academy of Medicine, Poland.
Wolska-Smolen
T
T
Blicharski
J
J
Zduńczyk
A
A
Sasiadek
U
U
Pituch-Noworolska
A
A
D000328:Adult; D004906:Erythrocyte Count; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007943:Leukemia, Hairy Cell / Q000628:therapy*; D008297:Male; D008854:Microscopy, Electron; D008875:Middle Aged; D010976:Platelet Count; D011947:Receptors, Antigen, B-Cell / Q000032:analysis; D011994:Recombinant Proteins; D013156:Splenectomy
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011947:Receptors, Antigen, B-Cell; D011994:Recombinant Proteins